Trial Profile

A phase I SAD/MAD study of AKG-100 in healthy volunteers and pulmonary TB patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AKG 100 (Primary)
Indications Pulmonary tuberculosis
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

01 Apr 2025 According to AKAGERA Medicines, Inc. media release, this study is being conducted at TASK clinical research site in Cape Town, South Africa.
01 Apr 2025 According to AKAGERA Medicines, Inc. media release, the company announced the completion of first cohort of this SAD/MAD study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com